Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanBusiness Wire • 4 days ago
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...
Share to Feed
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth PR...
PALM BEACH, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The use of Artificial Intelligence (AI) in medical diagnosis is taking broad strides in recent years and is...
Lantern Pharma Inc. (NASDAQ:LTRN Get Free Report) saw a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 68,000 shares...
Advancements in AI-Guided Drug Candidates and Financial Stability HighlightedRelated Stocks: LTRN...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...
Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will...
Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced an important milestone in its antibody-drug conjugate (ADC) program. In collaboration with...